| 杨丽姝,刘丽珠,韩波.甲磺酸阿帕替尼片单药治疗多线化疗失败后晚期卵巢癌 1例[J].安徽医药,2020,24(10):2079-2082. |
| 甲磺酸阿帕替尼片单药治疗多线化疗失败后晚期卵巢癌 1例 |
| Treatment with apatinib mesylate for advanced ovarian neoplasms after failure of multiline chemotherapy:a report of 1 case |
| |
| DOI：10.3969/j.issn.1009?6469.2020.10.041 |
| 中文关键词: 卵巢肿瘤 阿帕替尼 受体蛋白质酪氨酸激酶类 抗肿瘤联合化疗方案 血管生成抑制剂 |
| 英文关键词: Ovarian neoplasms Apatinib Receptor protein?tyrosine kinases Antineoplastic combined chemotherapy proto?cols Angiogenesis inhibitors |
| 基金项目:黑龙江省卫生计生委科研课题(2018257) |
|
| 摘要点击次数: 1852 |
| 全文下载次数: 481 |
| 中文摘要: |
| 目的观察甲磺酸阿帕替尼片(简称阿帕替尼)治疗多线化疗失败后晚期卵巢癌的疗效及安全性。方法报告 1例在哈尔滨医科大学附属第一医院 2016年 8月至 2017年 7月采用阿帕替尼治疗经多线以铂类为基础联合化疗失败的晚期卵巢癌的用法、疗效及安全性。结果阿帕替尼单药多线治疗晚期卵巢癌生存时间达到 13个月。主要不良反应为高血压及胸背疼痛，通过药物减量及对症治疗后得到控制。结论阿帕替尼多线治疗该例晚期卵巢癌有肯定的疗效，不良反应可耐受。需要大样本前瞻性的随机对照实验进一步确定阿帕替尼单药治疗卵巢癌的疗效及安全性。 |
| 英文摘要: |
| Objective To observe the efficacy and safety of apatinib mesylate tablets in the treatment of advanced ovarian neo?plasms after the failure of multiline chemotherapy.Methods The useage，efficacy and safety of apatinib were recorded and ana?lyzed in the treatment of one patient in First Affiliated Hospital of Harbin Medical University from August 2016 to July 2017 withadvanced ovarian cancer failed in multi?line platinum based chemotherapy.Results For the patient with advanced ovarian neo? plasms，apatinib as a multiline drug showed 13 months overall survival(OS).The major adverse reactions were hypertension and chest and back pain，which could be controlled by drug reduction and symptomatic treatment.Conclusion Apatinib is effective in multiline treatment of advanced ovarian neoplasms，and the adverse effects are tolerable.However，the efficacy and safety of apatinibin the treatment of ovarian neoplasms need to be further confirmed by large sample size prospective randomized controlled trials. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
